TY  - GEN
AU  - Kelly,R J
AU  - Thomas,A
AU  - Rajan,A
AU  - Chun,G
AU  - Lopez-Chavez,A
AU  - Szabo,E
AU  - Spencer,S
AU  - Carter,C A
AU  - Guha,U
AU  - Khozin,S
AU  - Poondru,S
AU  - Van Sant,C
AU  - Keating,A
AU  - Steinberg,S M
AU  - Figg,W
AU  - Giaccone,G
TI  - A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer
SN  - 1569-8041
PY  - 2014///0514
KW  - Adult
KW  - Aged
KW  - Antineoplastic Agents, Phytogenic
KW  - adverse effects
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Apoptosis
KW  - drug effects
KW  - Carboplatin
KW  - Carcinoma, Non-Small-Cell Lung
KW  - drug therapy
KW  - Disease-Free Survival
KW  - Female
KW  - Humans
KW  - Imidazoles
KW  - Inhibitor of Apoptosis Proteins
KW  - antagonists & inhibitors
KW  - Lung Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Naphthoquinones
KW  - Paclitaxel
KW  - Survival
KW  - Survivin
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
UR  - https://doi.org/10.1093/annonc/mdt249
ER  -